AMAG Pharmaceuticals, Inc. announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development. In collaboration with Dr. Krop, he will oversee the medical affairs strategy for the company's innovative marketed products and the pre-launch efforts for bremelanotide, as well as continue to build the medical affairs department. Most recently he served as vice president, medical affairs for bluebird bio where he built and led the medical affairs organization in preparation for their launch of gene therapy products for severe genetic diseases.